We are only expecting good news going forward

As most clued up investors know we are only expecting good news going forward with Starpharma

POSSIBLE REASONS

1. Dep Docetaxel exceeds expectations and still not has arrived at MTD (maximum tolerated dosage) or DLT (dose limiting toxicity)

2. Launching of the Vivagel coated condoms into the Japanese market by Okamoto. The launch was supposed to have taken place late last November on World Aids Day. However regulatory changes were made by the Japanese government specifically on labelling in of packaging of condoms. It was also stated by Starpharma that the launch would be a minimum of 3 to 6 months away. This deadline is now passed.

3. Regulatory submissions for VivaGel® Symptomatic Relief of bacterial vaginosis have been submitted to jurisdictions for approval. The term and trade sheets have been submitted to partners that will be manufacturing and selling into the retail market OTC (over the counter). Expect action in next few weeks to months

4. Agrochemical deals based on information is not too far away

5. Having said this there are so many non disclosed partnerships with big pharma and agro world players, a deal could be announced without surprise

6. Lastly the Astrazenica deal is icing on cake. They are progressing studies with Starpharma with the view to taking the dendrimer/cancer conjugate to FDA approved trials if the status quo does not change

All of points 1 to 4 have been factored in by analysts to have the share price of Starpharma around $1 plus range

Points 5 and 6 do not - this IS the bonus

Those that care to invest in Starpharma - now is the time. As can be seen with any biotech company - once announcement has been conveyed to market, the bird will have flown coup

Of course above is my opinion only and not investment advice